VÁPENATÁ SŮL ROSUVASTATINU (ROSUVASTATINUM CALCICUM) - परिणामों की खोज

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

palexia ir tapentadol (as hydrochloride) 100 mg tablet blister pack

seqirus pty ltd - tapentadol hydrochloride, quantity: 116.48 mg (equivalent: tapentadol, qty 100 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; magnesium stearate; lactose monohydrate; iron oxide yellow; purified talc; povidone; titanium dioxide; iron oxide red; polyvinyl alcohol; microcrystalline cellulose; macrogol 3350; iron oxide black - palexia ir is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

palexia ir tapentadol (as hydrochloride) 75 mg tablet blister pack

seqirus pty ltd - tapentadol hydrochloride, quantity: 87.36 mg (equivalent: tapentadol, qty 75 mg) - tablet, film coated - excipient ingredients: macrogol 3350; polyvinyl alcohol; iron oxide red; croscarmellose sodium; purified talc; lactose monohydrate; titanium dioxide; microcrystalline cellulose; povidone; magnesium stearate; iron oxide yellow - palexia ir is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

palexia ir tapentadol (as hydrochloride) 50 mg tablet blister pack

seqirus pty ltd - tapentadol hydrochloride, quantity: 58.24 mg (equivalent: tapentadol, qty 50 mg) - tablet, film coated - excipient ingredients: purified talc; titanium dioxide; croscarmellose sodium; polyvinyl alcohol; lactose monohydrate; macrogol 3350; microcrystalline cellulose; povidone; magnesium stearate - palexia ir is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.